1. Medtech Insight
  2. >>Business
  3. >>Deals

AstraZeneca Enlists Owlstone Medical To Identify Asthma And COPD Biomarkers

 
• By Catherine Longworth

Owlstone Medical has signed another major collaboration agreement with a big pharma company to use its breath biopsy services. The Cambridge, UK company is partnering with AstraZeneca to to identify novel breath biomarkers for asthma and COPD.

Owlstone Medical Ltd. has signed a collaboration agreement with AstraZeneca PLC to find novel breath biomarkers for asthma and COPD.

Under the terms of the agreement, Owlstone Medical will provide AstraZeneca with access to its Oxford-based Breath Biopsy Services including development of classification algorithms to identify breath biomarkers for precision...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Medtronic Eyes Up to $350M Tariff Hit in FY26, Leans On Cost Controls And Pricing Strategy

 
• By Shubham Singh

Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.

India-UK Free Trade Agreement Sets Stage For Medtech Growth, But Industry Demands Safeguards

 
• By Shubham Singh

Announced after three years of negotiation, the FTA eliminates tariffs on 99% of Indian product types, covering nearly all trade value, and reduces tariffs on 90% of UK products. Although not yet formally signed, the deal is being positioned by the Indian government as “transformative,” with an estimated economic impact of $6.4bn for the UK alone by 2040.

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By Shubham Singh

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.